SA518400460B1 - مركبات سيتوكين 1 المثبط للخلايا البلعمية واستخداماتها - Google Patents

مركبات سيتوكين 1 المثبط للخلايا البلعمية واستخداماتها

Info

Publication number
SA518400460B1
SA518400460B1 SA518400460A SA518400460A SA518400460B1 SA 518400460 B1 SA518400460 B1 SA 518400460B1 SA 518400460 A SA518400460 A SA 518400460A SA 518400460 A SA518400460 A SA 518400460A SA 518400460 B1 SA518400460 B1 SA 518400460B1
Authority
SA
Saudi Arabia
Prior art keywords
compounds
mic
relates
macrophage inhibitory
inhibitory cytokine
Prior art date
Application number
SA518400460A
Other languages
English (en)
Inventor
لارس فوج افيرسين
هينينج ثوجيرسين
اكسيانج جاو
هونجتاو جوان
سيباستين بيك جورجينسين
اكسيجيا زهانج
اوروم كريستين ساس-
بير نورجارد
كريستين تاج هانسين
وى وانج
Original Assignee
نوفو نورديسك ايه / اس
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by نوفو نورديسك ايه / اس filed Critical نوفو نورديسك ايه / اس
Publication of SA518400460B1 publication Critical patent/SA518400460B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الاختراع بمركبات سيتوكين 1 المثبط للخلايا البلعمية Macrophage Inhibitory Cytokine-1 (MIC-1). وبشكل أخص يتعلق بمركبات مشتملة على بولي ببتيد polypeptide سيتوكين 1 المثبط للخلايا البلعمية وامتداد الحمض الأميني amino acid للنهاية N، حيث يتكون الامتداد المذكور من 3 إلى 36 جزء حمض أميني وحيث يكون لدى المركب نقطة تساوي الجهد الكهربائيIsoelectric point ((pI محسوبة أقل من 6.5. ويكون لدى مركبات الاختراع نشاط سيتوكين 1 المثبط للخلايا البلعمية. يتعلق الاختراع أيضا بتركيبات دوائية مشتملة على مثل تلك المركبات والسواغات excipients المقبولة دوائيا، بالإضافة إلى الاستخدام الطبي للمركبات. شكل5
SA518400460A 2016-05-24 2018-11-19 مركبات سيتوكين 1 المثبط للخلايا البلعمية واستخداماتها SA518400460B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016083104 2016-05-24
CN2016103574 2016-10-27
PCT/EP2017/062583 WO2017202936A1 (en) 2016-05-24 2017-05-24 Mic-1 compounds and use thereof

Publications (1)

Publication Number Publication Date
SA518400460B1 true SA518400460B1 (ar) 2022-09-21

Family

ID=59009675

Family Applications (1)

Application Number Title Priority Date Filing Date
SA518400460A SA518400460B1 (ar) 2016-05-24 2018-11-19 مركبات سيتوكين 1 المثبط للخلايا البلعمية واستخداماتها

Country Status (18)

Country Link
US (3) US20190248852A1 (ar)
EP (1) EP3463412A1 (ar)
JP (1) JP7013390B2 (ar)
KR (1) KR102433503B1 (ar)
CN (1) CN109414471A (ar)
AU (1) AU2017269496B2 (ar)
BR (1) BR112018072034A2 (ar)
CA (1) CA3025251A1 (ar)
CL (1) CL2018003319A1 (ar)
CO (1) CO2018012258A2 (ar)
IL (1) IL262926A (ar)
MA (1) MA45113A (ar)
MX (1) MX2018014023A (ar)
PE (1) PE20190117A1 (ar)
PH (1) PH12018502465A1 (ar)
SA (1) SA518400460B1 (ar)
TW (1) TW201741333A (ar)
WO (1) WO2017202936A1 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2832581C (en) 2011-04-08 2022-08-23 Yumei Xiong Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
AU2014296107B2 (en) 2013-07-31 2018-07-26 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
MA45113A (fr) 2016-05-24 2019-04-10 Novo Nordisk As Composés mic-1 et leur utilisation
JP7134960B2 (ja) 2016-12-06 2022-09-12 セントビンセンツ ホスピタル シドニー リミテッド 肥満及び摂食障害の治療
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
PE20201350A1 (es) 2018-04-09 2020-11-30 Amgen Inc Proteinas de fusion del factor de diferenciacion de crecimiento 15
KR20210044244A (ko) 2018-08-10 2021-04-22 노파르티스 아게 Gfral 세포외 도메인 및 사용 방법
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
CN113597434B (zh) 2019-12-31 2022-07-01 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
EP4237438A1 (en) * 2020-10-27 2023-09-06 Beijing QL Biopharmaceutical Co., Ltd. Fusion proteins of gdf15 and use thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA954983B (en) * 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
AU3247699A (en) 1998-02-17 1999-09-06 Novo Nordisk A/S Lipase variant
AU2001259063A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
CN1152942C (zh) 2000-05-30 2004-06-09 华东理工大学 含载流子传输功能团的分子扭曲型电致发光材料及其应用
US7157235B2 (en) 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
PT2441466E (pt) 2004-04-13 2014-09-09 St Vincents Hosp Sydney Agente de inibição de mic-1
US7576190B2 (en) 2004-05-13 2009-08-18 Eli Lilly And Company FGF-21 fusion proteins
AU2005266184A1 (en) 2004-07-26 2006-02-02 Asterion Limited Linkers
JP2010505437A (ja) 2006-10-13 2010-02-25 ノボ ノルディスク ヘルス ケア アーゲー 塩基性タンパク質タグに融合したプロセシング酵素
MX2010001684A (es) 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
CN102361647B (zh) 2009-01-23 2018-02-16 诺沃-诺迪斯克有限公司 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
ES2705249T3 (es) * 2009-06-08 2019-03-22 Amunix Operating Inc Polipéptidos reguladores de glucosa y métodos para su producción y uso
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
CA2832581C (en) 2011-04-08 2022-08-23 Yumei Xiong Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
WO2013148117A1 (en) * 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
RU2704285C2 (ru) 2013-01-30 2019-10-25 Нгм Байофармасьютикалз, Инк. Композиции и способы применения для лечения метаболических расстройств
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
AU2014296107B2 (en) 2013-07-31 2018-07-26 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP6696915B2 (ja) * 2014-06-24 2020-05-20 ノヴォ ノルディスク アー／エス Ｍｉｃ−１融合タンパク質及びその使用
CR20170027A (es) 2014-07-30 2017-05-09 Ngm Biopharmaceuticals Inc Composiciones y métodos de uso para tratar trastornos metabólicos
WO2016069925A1 (en) * 2014-10-30 2016-05-06 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
TWI703161B (zh) 2014-10-31 2020-09-01 美商Ｎｇｍ生物製藥公司 用於治療代謝病症之組合物及方法
PL3236991T3 (pl) 2014-12-23 2019-12-31 Novo Nordisk A/S Pochodne fgf21 i ich zastosowania
MA41794A (fr) 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
US20170008928A1 (en) 2015-07-06 2017-01-12 Novo Nordisk A/S Novel peptides and peptide derivatives and uses thereof
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
CA3000293A1 (en) 2015-10-02 2017-04-06 Julius-Maximilians-Universitat Wurzburg Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
WO2017055612A1 (en) 2015-10-02 2017-04-06 Julius-Maximilians-Universität Würzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
MA45113A (fr) 2016-05-24 2019-04-10 Novo Nordisk As Composés mic-1 et leur utilisation
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途

Also Published As

Publication number Publication date
US20230212245A1 (en) 2023-07-06
US12006344B2 (en) 2024-06-11
US20210198331A1 (en) 2021-07-01
CO2018012258A2 (es) 2018-11-30
JP7013390B2 (ja) 2022-01-31
AU2017269496B2 (en) 2021-03-25
PE20190117A1 (es) 2019-01-16
US20190248852A1 (en) 2019-08-15
IL262926A (en) 2018-12-31
CA3025251A1 (en) 2017-11-30
BR112018072034A2 (pt) 2019-02-12
CN109414471A (zh) 2019-03-01
RU2018141829A3 (ar) 2020-10-07
WO2017202936A1 (en) 2017-11-30
PH12018502465A1 (en) 2019-04-08
RU2018141829A (ru) 2020-06-25
CL2018003319A1 (es) 2019-02-01
KR20190008290A (ko) 2019-01-23
MA45113A (fr) 2019-04-10
MX2018014023A (es) 2019-04-04
EP3463412A1 (en) 2019-04-10
TW201741333A (zh) 2017-12-01
JP2019520333A (ja) 2019-07-18
AU2017269496A1 (en) 2018-11-15
KR102433503B1 (ko) 2022-08-18

Similar Documents

Publication Publication Date Title
SA518400460B1 (ar) مركبات سيتوكين 1 المثبط للخلايا البلعمية واستخداماتها
PH12019550241A1 (en) Mic-1 compounds and uses thereof
WO2017011820A3 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
TW201613958A (en) MIC-1 fusion proteins and uses thereof
MY187047A (en) Selective pyy compounds and uses thereof
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
WO2014176373A3 (en) Interleukin-10 compositions and uses thereof
MY161773A (en) Amylin analogues and pharmaceutical compositions thereof
EP3674314A3 (en) Apelin polypeptides
MX2017014035A (es) Formas solidas novedosas.
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
WO2016199076A3 (en) Polymorphic forms of afatinib free base and afatinib dimaleate
MY197561A (en) Composition for increasing expression of pgc-1?
JOP20210295A1 (ar) أشكال صلبة لمثبط GlyT1
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
WO2015001541A3 (en) Pharmaceutical film composition
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
MX2018000418A (es) Derivados de amida que tienen actividad multimodal contra el dolor.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.